The purpose of this study was to examine the effects of eccentric contractions (Ecc) on cation (i.e., K⁺, Na⁺ and Ca²⁺) regulation in skeletal muscle. The left anterior crural muscles of male Wistar rats were subjected in vivo to either Ecc or isometric contrations (Iso) for 200 cycles. The extensor digitorum longus and tibialis anterior muscles were removed immediately after and 2, 4 and 6 days following contractions and used for measures of force output and biochemical analyses, respectively. Ecc led to a 75% decrease in maximal tetanic force. Decreased force output did not revert to pre-exercise levels during 6 days of recovery. Sarcoplasmic reticulum (SR) Ca²⁺-ATPase activity was reduced by 52 and 60% 4 and 6 days after Ecc, respectively. The reduction in catalytic activity after 6 days was accompanied by a 63% decrease in SR Ca²⁺-ATPase protein and an approximately 3.5-fold increase in calpain activity. Na⁺-K⁺-ATPase acticity was decreased by 23% immediately after Ecc and restored during 2 days of recovery. These alterations were specific for Ecc and not observed for Iso. These results suggest that disturbances in cation regulation may account, at least partly, for Ecc-induced decreases in force and power which can take a number of days to recover and that the decrease in SR Ca²⁺-ATPase activity would result from the degradation of the enzyme.

Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disease that is characterized by the formation of heterotopic bone tissues in soft tissues, such as skeletal muscle, ligament, and tendon. It is difficult to remove such heterotopic bones via internal medicine or invasive procedures. The identification of activin A receptor, type I (ACVR1)/ALK2 gene mutations associated with FOP has allowed the genetic diagnosis of FOP. The ACVR1/ALK2 gene encodes the ALK2 protein, which is a transmembrane kinase receptor in the transforming growth factor-β family. The relevant mutations activate intracellular signaling in vitro and induce heterotopic bone formation in vivo. Activin A is a potential ligand that activates mutant ALK2 but not wild-type ALK2. Various types of small chemical and biological inhibitors of ALK2 signaling have been developed to establish treatments for FOP. Some of these are in clinical trials in patients with FOP.
Activins ; Bone and Bones ; Diagnosis ; Humans ; In Vitro Techniques ; Internal Medicine ; Ligaments ; Muscle, Skeletal ; Myositis Ossificans* ; Osteogenesis ; Phosphotransferases ; Tendons ; Transforming Growth Factor beta